Related Experiment Video
Updated: Mar 30, 2026
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary
Simona Salati1, Roberta Zini1, Simona Nuzzo2
1Life Sciences Department University of Modena and Reggio Emilia, Centre for Regenerative Medicine, via Gottardi N.100, Modena, 41125, Italy.
Abstract:
Primary myelofibrosis (PMF) is a Myeloproliferative Neoplasm (MPN) characterized by megakaryocyte hyperplasia, progressive bone marrow fibrosis, extramedullary hematopoiesis and transformation to Acute Myeloid Leukemia (AML). A number of phenotypic driver (JAK2, CALR, MPL) and additional subclonal mutations have been described in PMF, pointing to a complex genomic landscape. To discover novel genomic lesions that can contribute to disease phenotype and/or development, gene expression and copy number signals were integrated and several genomic abnormalities leading to a concordant alteration in gene expression levels were identified. In particular, copy number gain in the polyamine oxidase (PAOX) gene locus was accompanied by a coordinated transcriptional up-regulation in PMF patients. PAOX inhibition resulted in rapid cell death of PMF progenitor cells, while sparing normal cells, suggesting that PAOX inhibition could represent a therapeutic strategy to selectively target PMF cells without affecting normal hematopoietic cells' survival. Moreover, copy number loss in the chromatin modifier HMGXB4 gene correlates with a concomitant transcriptional down-regulation in PMF patients. Interestingly, silencing of HMGXB4 induces megakaryocyte differentiation, while inhibiting erythroid development, in human hematopoietic stem/progenitor cells. These results highlight a previously un-reported, yet potentially interesting role of HMGXB4 in the hematopoietic system and suggest that genomic and transcriptional imbalances of HMGXB4 could contribute to the aberrant expansion of the megakaryocytic lineage that characterizes PMF patients.
Insights
Researchers identified novel genetic targets in Primary Myelofibrosis (PMF). Inhibiting the PAOX gene selectively killed PMF cells, while HMGXB4 gene alterations influenced megakaryocyte development, offering new therapeutic avenues for this myeloproliferative neoplasm.
Area of Science:
- Hematology
- Genomics
- Molecular Biology
Background:
- Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) marked by bone marrow fibrosis and transformation to acute myeloid leukemia (AML).
- Known driver mutations (JAK2, CALR, MPL) and subclonal mutations contribute to PMF's complex genomic landscape.
Purpose of the Study:
- To identify novel genomic alterations and their impact on gene expression in PMF.
- To explore potential therapeutic targets within the identified genomic abnormalities.
Main Methods:
- Integrated gene expression and copy number analysis in PMF patients.
- Functional studies involving gene inhibition (PAOX) and gene silencing (HMGXB4) in hematopoietic cells.
Main Results:
- Copy number gain of the polyamine oxidase (PAOX) gene correlated with its increased expression, and PAOX inhibition selectively killed PMF progenitor cells.
- Copy number loss of the HMGXB4 gene correlated with its decreased expression, and HMGXB4 silencing induced megakaryocyte differentiation while inhibiting erythroid development.
Conclusions:
- PAOX inhibition presents a potential therapeutic strategy for selectively targeting PMF cells.
- Genomic and transcriptional dysregulation of HMGXB4 may contribute to the megakaryocytic lineage expansion characteristic of PMF.
